Read the latest insights we've been sharing on LinkedIn
June 7, 2025
Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders.
by Real Endpoints
Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders. Thing is these implications could also easily apply to any number of drugs in other competitive disease spaces, where there is high budget impact and more than a little uncertainty about clinical benefit.
LinkedIn >
June 5, 2025
Key Market Access Insights from Sanofi’s $9B Blueprint Deal
by Real Endpoints
Sanofi’s $9B acquisition of Blueprint Medicines brings a welcome burst of heat to biotech’s long dealmaking winter. And it offers a few clear reminders about how access and reimbursement shape commercial value today.
LinkedIn >
May 28, 2025
Real Endpoints’ CEO at Swiss HLG Conference
by Real Endpoints
Thanks to the team at SwissHLG for inviting our CEO Jeff Berkowitz to discuss how early stage biotechs - and the investors who fund them - should invest in critical market access capabilities to drive commercial success.
LinkedIn >
May 20, 2025
Supporting Patients Amid Rising Cost-Sharing Trends
by Real Endpoints
President Trump today signed an Executive order that, despite the pomp and circumstance, provided little to no detail on how it would be carried out. As expected, the order highlights Trump’s intent to use a “Most Favored Nation” strategy, in which U.S. prices will be tied to the lowest drug prices paid by developed countries.
LinkedIn >
April 25, 2025
Real Endpoints at Asembia 2025
by Real Endpoints
And we are off and running at Asembia 2025. If you would like to talk market access, product reimbursement, or patient assistance, the Real Endpoints team still has some open spots to meet April 27, 28, and 29. Connect with us via a direct message or email @info@realendpoints.com.
LinkedIn >